The use of next-generation sequencing in multi-gene targeted panel testing identified a considerable number of actionable mutations among patients with malignant melanoma, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Conferences
Durable response to T-VEC, GM-CSF linked to longer OS
Patients with unresected stage IIIB, stage IIIc or stage IV melanoma who achieved durable response to either talimogene laherparepvec or granulocyte-macrophage colony–stimulating factor demonstrated longer OS than those who did not achieve a durable response, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Simultaneous treatment with ipilimumab, nivolumab improves outcomes in advanced melanoma
Patients with treatment-naive advanced melanoma who underwent simultaneous treatment with ipilimumab and nivolumab demonstrated longer PFS and a higher objective response rate than patients treated with ipilimumab alone, according to phase 2 study results presented at the American Association for Cancer Research Annual Meeting.
SLNB used in patients with thin melanomas prior to guidelines
Sentinel lymph node biopsy was used in patients with thin melanomas who did not have high-risk features and who had a very low risk for sentinel lymph node positivity prior to guidelines recommending against its use in this setting, according to observational study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.